

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Attorney Docket No.:

0508-1107

Application No.:

NEW NATIONAL PHASE

Applicant:

Christophe GUILLON et al.

Filing Date:

July 12, 2004

Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
/L.H./	96/28189	9/19/1996	PCT				
/L.H./	2 792 204	10/20/2000	FRANCE				
/L.H./	99/27958	6/10/1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/L.H./	Orsini. "Inhibition of Human Immunodeficiency Virus Type 1 and Type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm," J. Virol., vol. 70, no. 11, November 1996 (1996-11), pages 8055-8063, XP002214873
/L.H./	Goldstein, "HIV - Tat protein as a potential AIDS vaccine," Nature Medicine, Nature Publishing, Co., US, vol. 2, no. 9, September 1996 (1996-09), pages 960-964, XP002129594 ISSN: 1078-8956.
/L.H./	Le Buanec et al., "A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat Toxoid," Biomed & Pharm. 1998, vol. 52, pages 431-435, XP000867754.
/L.H./	Brake et al., "Characterization of Murine Monoclonal Antibodies to the Tat Protein from Human Immunodeficiency Virus Type 1," Journal of Virology, The American Society for Microbiology, US, Vol. 64, Feb 1990 (1990-02), p. 962-965, XP002912805, ISSN:0022-538X
/L.H./	Caselli et al., "DNA Immunization with HIV-1 tat Mutated in the trans Activation Domain Induces Humoral and Cellular Immune Responses Against Wild-Type Tat", The Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, vol. 162, no. 9, May 1, 1999 (1999-05-01), pages 5631-5638, XP002129597, ISSN: 0022-1767

EXAMINER:

/Louise Humphrey/

DATE CONSIDERED

09/11/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* English language abstract provided for the Examiner's convenience

Best Available Copy

Y&T July 12, 2004